Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of ZG19018 in KRAS G12C-mutated advanced solid tumors
CTR20220296Phase 2Active
- Sponsor
- Zelgen
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ocatini in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), colorectal cancer (CRC), sponsored by Zelgen. Started May 2022; status: active.
02
Drugs
ocatini
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20220296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220296.